Mode
Text Size
Log in / Sign up
Phase 1 N=18 Randomized Other

Taste Assessment Study of SHP429 in Healthy Adult Subjects

Healthy

Enrolled (actual)
18
Serious AEs
0.0%
Results posted
Apr 2015
Primary outcome: Primary: Number of Participants With Positive Responses to Palatability Assessment of The Taste of Mesalamine — 17; 16; 13 participants

Study Design & Population

Study type
Interventional
Phase
Phase 1
Interventions
Mesalamine (Drug)
Age
Adult · 18+ yrs
Sex
All
Sponsor
Shire
Primary completion
Jun 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Positive Responses to Palatability Assessment of The Taste of Mesalamine
17; 16; 13
PRIMARY
Number of Participants Who Detected an Aftertaste of Mesalamine
0; 4; 1
PRIMARY
Number of Participants With Positive Responses to Palatability Assessment of The Aftertaste of Mesalamine
0; 3; 1
PRIMARY
Number of Participants Willing to Take Mesalamine Via Treatment Method on a Regular Basis
18; 17; 18
SECONDARY
Number of Participants Who Experienced an Adverse Event
0; 2
SECONDARY
Number of Participants With Potentially Clinically Important Laboratory Results
0; 0; 3
SECONDARY
Number of Participants With Potentially Clinically Important Vital Signs
SECONDARY
Number of Participants With Potentially Clinically Important Electrocardiogram (ECG) Results

Summary

The purpose of this study is to compare the palatability of SHP429 capsule contents delivered via 3 means of administration (sprinkled on yogurt, sprinkled on applesauce, and emptied into a cup and administered with water).

Eligibility Criteria

Inclusion Criteria

  • normal, healthy, adult male and female volunteers, without evidence of active or chronic disease
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02125292). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search